Boston Scientific Co. (NYSE:BSX) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC reduced its position in Boston Scientific Co. (NYSE:BSX) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,120,564 shares of the medical equipment provider’s stock after selling 4,939 shares during the period. Calamos Advisors LLC owned about 0.08% of Boston Scientific worth $64,780,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Xponance Inc. lifted its stake in shares of Boston Scientific by 7.0% in the fourth quarter. Xponance Inc. now owns 191,998 shares of the medical equipment provider’s stock worth $11,099,000 after buying an additional 12,537 shares during the last quarter. AIA Group Ltd increased its position in Boston Scientific by 86.4% during the fourth quarter. AIA Group Ltd now owns 22,317 shares of the medical equipment provider’s stock worth $1,290,000 after acquiring an additional 10,346 shares during the period. Cambridge Trust Co. increased its position in Boston Scientific by 14.7% during the fourth quarter. Cambridge Trust Co. now owns 3,647 shares of the medical equipment provider’s stock worth $211,000 after acquiring an additional 467 shares during the period. Twin Capital Management Inc. increased its position in Boston Scientific by 8.6% during the fourth quarter. Twin Capital Management Inc. now owns 22,996 shares of the medical equipment provider’s stock worth $1,329,000 after acquiring an additional 1,816 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt increased its position in Boston Scientific by 2.8% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 67,823 shares of the medical equipment provider’s stock worth $3,921,000 after acquiring an additional 1,876 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In related news, CFO Daniel J. Brennan sold 13,662 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the sale, the chief financial officer now directly owns 271,542 shares in the company, valued at approximately $17,883,756.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Daniel J. Brennan sold 13,662 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the sale, the chief financial officer now directly owns 271,542 shares in the company, valued at approximately $17,883,756.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the completion of the sale, the executive vice president now owns 50,638 shares in the company, valued at $3,509,213.40. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock worth $3,418,529 in the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.8 %

Boston Scientific stock traded down $0.54 during trading hours on Thursday, reaching $67.42. 5,946,614 shares of the company’s stock traded hands, compared to its average volume of 6,369,346. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $69.21. The firm has a market capitalization of $98.91 billion, a price-to-earnings ratio of 63.51, a PEG ratio of 2.39 and a beta of 0.78. The firm’s 50 day moving average is $67.17 and its 200-day moving average is $59.68.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same period in the prior year, the company posted $0.45 EPS. On average, analysts predict that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Raymond James boosted their target price on shares of Boston Scientific from $67.00 to $73.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 1st. BTIG Research reissued a “buy” rating and issued a $64.00 price target on shares of Boston Scientific in a report on Friday, December 29th. StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Needham & Company LLC boosted their price target on shares of Boston Scientific from $60.00 to $71.00 and gave the company a “buy” rating in a report on Thursday, February 1st. Finally, Wells Fargo & Company upped their target price on shares of Boston Scientific from $70.00 to $72.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Two analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $68.50.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.